NCT02549937: A Multi-Center, Open-Label Study of Sulfatinib (HMPL-012) in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase; Patients with a neuroendocrine tumor are eligible for both the escalation and expansion phase
Exclusions: Untreated unstable brain metastases requiring steroids- see trial for details

Comments are closed.

Up ↑